making biosimilars more accessible
A Novel Approach
Biosimilars are expected to save hundreds of billions of dollars to American patients, but only if they come available quickly and widely. Since 2009, when the BPCIA allowed biosimilars in the US, only seven products have been approved, and most of them are under litigation and have little impact on the cost of these essential biological drugs. Karyo Biologics is a novel idea and plan company, whose principals have decades of experience of developing biosimilars including 351(k) filings. The new model presents an opportunity for companies to market biosimilar products under their own label. Karyo provides commercial supply, and you do the marketing and distribution. No capital investment, no long delays and above all no limit on how many products you can have. Karyo sees this as the only solution to make biosimilars accessible: available and affordable. Find out more.